Long acting GLP-1 receptor agonist (injectable)

Ebenatide 2 mg injection once weekly

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

EBENAT_SC_2MG_QW

Mechanism: GLP-1 receptor agonist; daily or weekly (liraglutide; dulaglutide; semaglutide; exenatide extended release; albiglutide; efpeglenatide; loxenatide; taspoglutide and others)
Trials: 1
Participants in these arms: 52

All doses pooled: Ebenatide injection

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 20 to 36 (target week 26)	Placebo	MD -3.33 (-8.97 to 2.38)	0.62

Trials

NCT05990374
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
2023 · 78 randomized · 52 weeks

Ebenatide 2 mg injection once weekly

Related

Effects across outcomes

Trials